Aim of this study was to investigate the anti-HBs antibody persistence and immune memory to hepatitis B virus in adult celiacs vaccinated as adolescents and the effect of a booster administration in non-protected individuals. Eleven years after primary vaccination, the proportion of vaccinees with titres ≥10 mIU/ml and antibody geometric mean concentrations (GMCs) were lower among celiac patients than among controls (68.6% vs 91.7%, p < 0.01; GMCs 29.38 mIU/ml vs 250.6 mIU/ml, p < 0.001). Participants with anti-HBs below 10 mIU/ml received a booster dose and were retested 2 weeks later to assess the anamnestic response. Post-booster anti-HBs levels were still <10 mIU/ml in 71.4% celiacs and 25% controls (p < 0.01). Our findings indicate that the prevalence of seroprotective levels of anti-HBs detected eleven years after primary immunization as well as the frequency of response to a booster dose of vaccine are lower in celiac patients compared to healthy controls.
Long-term antibody persistence and immune memory to hepatitis B virus in adult celiac patients vaccinated as adolescents / F. Zingone, F. Morisco, A.R. Zanetti, L. Romano’, G. Portella, P. Capone, P. Andreozzi, R. Tortora, C. Ciacci. - In: VACCINE. - ISSN 0264-410X. - 29:5(2011), pp. 1005-1008. [10.1016/j.vaccine.2010.11.060]
Long-term antibody persistence and immune memory to hepatitis B virus in adult celiac patients vaccinated as adolescents
A.R. Zanetti;L. Romano’;
2011
Abstract
Aim of this study was to investigate the anti-HBs antibody persistence and immune memory to hepatitis B virus in adult celiacs vaccinated as adolescents and the effect of a booster administration in non-protected individuals. Eleven years after primary vaccination, the proportion of vaccinees with titres ≥10 mIU/ml and antibody geometric mean concentrations (GMCs) were lower among celiac patients than among controls (68.6% vs 91.7%, p < 0.01; GMCs 29.38 mIU/ml vs 250.6 mIU/ml, p < 0.001). Participants with anti-HBs below 10 mIU/ml received a booster dose and were retested 2 weeks later to assess the anamnestic response. Post-booster anti-HBs levels were still <10 mIU/ml in 71.4% celiacs and 25% controls (p < 0.01). Our findings indicate that the prevalence of seroprotective levels of anti-HBs detected eleven years after primary immunization as well as the frequency of response to a booster dose of vaccine are lower in celiac patients compared to healthy controls.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.